Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease

• Published in: BMC medical informatics and decision making Vol. 18; no. 1; p. 138
• Main Authors: Cohen, Shani, Waks, Zeev, Elm, Jordan J, Gordon, Mark Forrest, Grachev, Igor D, Navon-Perry, Leehee, Fine, Shai, Grossman, Iris, Papapetropoulos, Spyros, Savola, Juha-Matti
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20-12-2018; BioMed Central; BMC
• Subjects: Aged; Analysis; Biomarkers; Care and treatment; Clinical Studies as Topic; Clinical trials; Compliance; Correlation analysis; Data collection; Data transmission; Digital media; Digital trials; Drugs; Female; Gait; Heart rate; Humans; Huntington Disease - diagnosis; Huntington Disease - psychology; Huntington Disease - therapy; Huntington's disease; Huntingtons disease; Male; Medical research; Middle Aged; Mobile Applications; Motor task performance; Motors; Movement disorders; Neurodegenerative diseases; Neurology; Parkinson disease; Parkinson Disease - diagnosis; Parkinson Disease - psychology; Parkinson Disease - therapy; Parkinson's disease; Patient Compliance; Patients; Pharmaceuticals; Reduction; Remote clinical trials; Remote monitoring; Research Design; Schedules; Sensors; Smartphone; Smartphones; Smartwatches; Time Factors; Wearables; Smartphones; Remote clinical trials; Compliance; Digital trials; Huntington disease; Wearables; Sensors; Parkinson’s disease
• ISSN: 1472-6947; 1472-6947
• DOI: 10.1186/s12911-018-0714-7

A growing number of clinical trials use various sensors and smartphone applications to collect data outside of the clinic or hospital, raising the question to what extent patients comply with the unique requirements of remote study protocols. Compliance is particularly important in conditions where patients are motorically and cognitively impaired. Here, we sought to understand patient compliance in digital trials of two such pathologies, Parkinson's disease (PD) and Huntington disease (HD).
Patient compliance was assessed in two remote, six-month clinical trials of PD (n = 51, Clinician Input Study funded by the Michael J. Fox Foundation for Parkinson's Research) and HD (n = 17, sponsored by Teva Pharmaceuticals). We monitored four compliance metrics specific to remote studies: smartphone app-based medication reporting, app-based symptoms reporting, the duration of smartwatch data streaming except while charging, and the performance of structured motor tasks at home.
While compliance over time differed between the PD and HD studies, both studies maintained high compliance levels for their entire six month duration. None (- 1%) to a 30% reduction in compliance rate was registered for HD patients, and a reduction of 34 to 53% was registered for the PD study. Both studies exhibited marked changes in compliance rates during the initial days of enrollment. Interestingly, daily smartwatch data streaming patterns were similar, peaking around noon, dropping sharply in the late evening hours around 8 pm, and having a mean of 8.6 daily streaming hours for the PD study and 10.5 h for the HD study. Individual patients tended to have either high or low compliance across all compliance metrics as measured by pairwise correlation. Encouragingly, predefined schedules and app-based reminders fulfilled their intended effect on the timing of medication intake reporting and performance of structured motor tasks at home.
Our findings suggest that maintaining compliance over long durations is feasible, promote the use of predefined app-based reminders, and highlight the importance of patient selection as highly compliant patients typically have a higher adherence rate across the different aspects of the protocol. Overall, these data can serve as a reference point for the design of upcoming remote digital studies.
Trials described in this study include a sub-study of the Open PRIDE-HD Huntington's disease study (TV7820-CNS-20016), which was registered on July 7th, 2015, sponsored by Teva Pharmaceuticals Ltd., and registered on Clinicaltrials.gov as NCT02494778 and EudraCT as 2015-000904-24 .